Home >> Life Sciences >> Healthcare

Global Genetic Testing Market Outlook (2015-2022)

Published: Jul-2015 | Format: PDF | Stratistics MRC | Number of pages: 90 | Code: MRS - 28326

The Global Genetic Testing Market accounted for $3.2 billion in 2014 and is expected to grow at a CAGR of 9.26% to reach $6.5 billion by 2022. The factors contributing to the market growth include aging population, growing awareness, availability of direct to consumer tests and increasing incidence of genetic disorder. However factors such as high cost for testing and reimbursement issues are inhibiting the growth of the market. Genetic testing for cancer is likely to be the fastest growing segment during the forecast period. Increasing incidence of genetic diseases is providing more opportunities for genetic testing along with the rise in personalized medicine. The federal agencies who play a significant role in regulating genetic tests are Food and Drug Administration (FDA), Federal Trade Commission (FTC) and Center for Medicare and Medicaid services (CMS).

Global Genetic Testing Market is segmented on the basis of application and geography. By Application, the market is categorized into Cancer Genetic Testing Market, Prenatal Genetic Testing Market, Pharmacogenomics Genetic Testing Market and Predisposition Cancer Genetic Testing Market. By geography, market is segmented into North America, Europe, Asia Pacific and Rest of the World. North America leads the Genetic Testing Market followed by Europe.

Some of the key players in Genetic Testing Market include Abbott Laboratories, Biocartis SA, Applied Biosystems Inc., Celera Group, AutoGenomics Inc., Roche Diagnostics Limited, IntegraGen S.A, Transgenomic, Inc., Molecular Inc. and Luminex Corporation.

What our report offers:

- Market share assessments for the regional and country level segments
- Market share analysis of the top industry players 
- Strategic recommendations for the new entrants
- Market forecasts for a minimum of 8 years of all the mentioned segments, sub segments and the regional markets
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
1 Executive Summary

2 Preface
2.1 Abstract
2.2 Research Scope
2.3 Research Methodology
2.4 Research Sources

3 Market Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats

4 Porters Five Force Analysis
4.1 Bargaining power of suppliers 
4.2 Bargaining power of buyers 
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry

5Global Genetic TestingMarket, By Applications 
5.1 Cancer Genetic Testing Market
5.2 Prenatal Genetic Testing Market 
5.3 Pharmacogenomics Genetic Testing Market
5.4 Predisposition Cancer Genetic Testing Market 

6 Global Genetic TestingMarket, By Geography 
6.1 North America
6.1.1 US
6.1.2 Canada
6.2 Europe
6.2.1 Germany
6.2.2 France
6.2.3 Italy
6.2.4 UK
6.2.5 Spain
6.3 Asia Pacific
6.3.1 Japan
6.3.2 China
6.3.3 India
6.3.4 Australia
6.3.5 Newzealand
6.3.6 Rest of Asia
6.4 Rest of the World
6.4.1 Latin America
6.4.2 Middle East
6.4.3 Africa
6.4.4 Others

7 Key Developments
7.1 Agreements, Partnerships, Collaborations and Joint Ventures 
7.2 Acquisitions & Mergers
7.3 New Product Launch
7.4 Expansions
7.5 Other Key Strategies

8 Company Profiling
8.1 Abbott Laboratories
8.2 Biocartis SA
8.3 Applied Biosystems Inc.
8.4 Celera Group
8.5 AutoGenomics Inc.
8.6 Roche Diagnostics Limited 
8.7 IntegraGen S.A
8.8 Transgenomic, Inc.
8.9 Molecular Inc. 
8.10 Luminex Corporation

List of Tables
1 Global Genetic TestingMarket Outlook, By Applications (2012-2022) ($MN)
2 Global Genetic TestingMarket Outlook, By Cancer Genetic Testing Market(2012-2022) ($MN)
3 Global Genetic TestingMarket Outlook, By Prenatal Genetic Testing Market (2012-2022) ($MN)
4 Global Genetic TestingMarket Outlook, By Pharmacogenomics Genetic Testing Market (2012-2022) ($MN)
5 Global Genetic TestingMarket Outlook, By Predisposition Cancer Genetic Testing Market(2012-2022) ($MN)
6 North America Genetic TestingMarket Outlook, By Applications (2012-2022) ($MN)
7 North America Genetic TestingMarket Outlook, By Cancer Genetic Testing Market(2012-2022) ($MN)
8 North America Genetic TestingMarket Outlook, By Prenatal Genetic Testing Market (2012-2022) ($MN)
9 North America Genetic TestingMarket Outlook, By Pharmacogenomics Genetic Testing Market (2012-2022) ($MN)
10 North America Genetic TestingMarket Outlook, By Predisposition Cancer Genetic Testing Market(2012-2022) ($MN)
11 Europe Genetic TestingMarket Outlook, By Applications (2012-2022) ($MN)
12 Europe Genetic TestingMarket Outlook, By Cancer Genetic Testing Market(2012-2022) ($MN)
13 Europe Genetic TestingMarket Outlook, By Prenatal Genetic Testing Market (2012-2022) ($MN)
14 Europe Genetic TestingMarket Outlook, By Pharmacogenomics Genetic Testing Market (2012-2022) ($MN)
15 Europe Genetic TestingMarket Outlook, By Predisposition Cancer Genetic Testing Market(2012-2022) ($MN)
16 Asia Pacific Genetic TestingMarket Outlook, By Applications (2012-2022) ($MN)
17 Asia Pacific Genetic TestingMarket Outlook, By Cancer Genetic Testing Market(2012-2022) ($MN)
18 Asia Pacific Genetic TestingMarket Outlook, By Prenatal Genetic Testing Market (2012-2022) ($MN)
19 Asia Pacific Genetic TestingMarket Outlook, By Pharmacogenomics Genetic Testing Market (2012-2022) ($MN)
20 Asia Pacific Genetic TestingMarket Outlook, By Predisposition Cancer Genetic Testing Market(2012-2022) ($MN)
21 Rest Of The World Genetic TestingMarket Outlook, By Applications (2012-2022) ($MN)
22 Rest Of The World Genetic TestingMarket Outlook, By Cancer Genetic Testing Market(2012-2022) ($MN)
23 Rest Of The World Genetic TestingMarket Outlook, By Prenatal Genetic Testing Market (2012-2022) ($MN)
24 Rest Of The World Genetic TestingMarket Outlook, By Pharmacogenomics Genetic Testing Market (2012-2022) ($MN)
25 Rest Of The World Genetic TestingMarket Outlook, By Predisposition Cancer Genetic Testing Market(2012-2022) ($MN)

                        
            

Inquiry For Buying

Please fill your details below, to inquire about this report:
Indicates required fields

Request Sample

Please fill your details below, to receive sample report:
Indicates required fields


Related Reports

Catenin Beta 1 (Beta Catenin or CTNNB1) - Pipeline Review, H2 2017

Oct-2017 | Global Markets Direct | Pages : 57 | Code : MRS-172735 | 3500

Catenin Beta 1 (Beta Catenin or CTNNB1) - Pipeline Review, H2 2017 Summary Catenin Beta 1 (Beta Catenin or CTNNB1) pipeline Target constitutes close to 14 molecules. Out of which approximately 10 molecules are developed by companies and remaining by the universities/institutes. The latest report Catenin Beta 1 (Beta Catenin or CTNNB1) - Pipeline Review, H2 2017, outlays comprehensive information on the Catenin Beta 1 (Beta Catenin or CTNNB1) targeted therapeutics, complete with analysis b Read more

Transthyretin (ATTR or Prealbumin or TBPA or TTR) - Pipeline Review, H2 2017

Oct-2017 | Global Markets Direct | Pages : 74 | Code : MRS-172734 | 3500

Transthyretin (ATTR or Prealbumin or TBPA or TTR) - Pipeline Review, H2 2017 Summary According to the recently published report 'Transthyretin (ATTR or Prealbumin or TBPA or TTR) - Pipeline Review, H2 2017'; Transthyretin (ATTR or Prealbumin or TBPA or TTR) pipeline Target constitutes close to 15 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes. Transthyretin (ATTR or Prealbumin or TBPA or TTR) - Transthyretin is Read more

Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Pipeline Review, H2 2017

Oct-2017 | Global Markets Direct | Pages : 107 | Code : MRS-172733 | 3500

Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Pipeline Review, H2 2017 Summary Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Complement component 5 is a protein is encoded by the C5 gene. Activation of C5 by a C5 convertase initiates the spontaneous assembly of the late complement components, C5-C9, into the membrane attack complex. C5b has a transient binding site for C6. The C5b-C6 complex is the fou Read more

Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Pipeline Review, H2 2017

Oct-2017 | Global Markets Direct | Pages : 42 | Code : MRS-172732 | 3500

Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Pipeline Review, H2 2017 Summary Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) pipeline Target constitutes close to 7 molecules. Out of which approximately 7 molecules are developed by Companies. The latest report Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Pipeline Review, H2 2017, outlays comprehensive information on the Protein Kinase C Epsilon Type (nPKC Epsilon Read more

Aurora Kinase C (Aurora 3 or Aurora/IPL1 Related Kinase 3 or Aurora/IPL1/Eg2 Protein 2 or Serine/Threonine Protein Kinase 13 or Serine/Threonine Protein Kinase Aurora C or AURKC or EC 2.7.11.1) - Pipeline Review, H2 2017

Oct-2017 | Global Markets Direct | Pages : 32 | Code : MRS-172731 | 3500

Aurora Kinase C (Aurora 3 or Aurora/IPL1 Related Kinase 3 or Aurora/IPL1/Eg2 Protein 2 or Serine/Threonine Protein Kinase 13 or Serine/Threonine Protein Kinase Aurora C or AURKC or EC 2.7.11.1) - Pipeline Review, H2 2017 Summary According to the recently published report 'Aurora Kinase C - Pipeline Review, H2 2017'; Aurora Kinase C (Aurora 3 or Aurora/IPL1 Related Kinase 3 or Aurora/IPL1/Eg2 Protein 2 or Serine/Threonine Protein Kinase 13 or Serine/Threonine Protein Kinase Aurora C or AUR Read more

Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) - Pipeline Review, H2 2017

Oct-2017 | Global Markets Direct | Pages : 58 | Code : MRS-172730 | 3500

Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) - Pipeline Review, H2 2017 Summary Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) - Glycogen synthase kinase 3 beta also known as GSK3B is an enzyme encoded by the GSK3B. It constitutively activate protein kinase that acts as a negative regulator in the hormonal control of glucose homeostasis, Wnt signaling and reg Read more

Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) - Pipeline Review, H2 2017

Oct-2017 | Global Markets Direct | Pages : 50 | Code : MRS-172729 | 3500

Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) - Pipeline Review, H2 2017 Summary Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) pipeline Target constitutes close to 11 molecules. Out of which approximately 9 molecules are developed by companies and remaining by the universities/institutes. The latest report Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) - Pipeline Review, H2 2017, outlays comprehensive information on the Glucokinase (Hex Read more

Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Pipeline Review, H2 2017

Oct-2017 | Global Markets Direct | Pages : 112 | Code : MRS-172728 | 3500

Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Pipeline Review, H2 2017 Summary According to the recently published report 'Telomerase Reverse Transcriptase - Telomerase Reverse Transcriptase'; Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) pipeline Target constitutes close to 31 molecules. Out of which approximately 25 m Read more

Dual Specificity Protein Kinase TTK (Cancer/Testis Antigen 96 or Monopolar Spindle 1 Like 1 or Phosphotyrosine Picked Threonine Protein Kinase or TTK or EC 2.7.12.1) - Pipeline Review, H2 2017

Oct-2017 | Global Markets Direct | Pages : 36 | Code : MRS-172727 | 3500

Dual Specificity Protein Kinase TTK (Cancer/Testis Antigen 96 or Monopolar Spindle 1 Like 1 or Phosphotyrosine Picked Threonine Protein Kinase or TTK or EC 2.7.12.1) - Pipeline Review, H2 2017 Summary Dual Specificity Protein Kinase TTK (Cancer/Testis Antigen 96 or Monopolar Spindle 1 Like 1 or Phosphotyrosine Picked Threonine Protein Kinase or TTK or EC 2.7.12.1) - Dual specificity protein kinase TTK is an enzyme encoded by the TTK gene. It is associated with cell proliferation, essentia Read more

Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) - Pipeline Review, H2 2017

Oct-2017 | Global Markets Direct | Pages : 145 | Code : MRS-172726 | 3500

Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) - Pipeline Review, H2 2017 Summary Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) pipeline Target constitutes close to 31 molecules. Out of which approximately 27 molecules are developed by companies Read more

Single User | $(USD)4150 View Pricing